X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-28 | PLUR | Pluri Inc. | Manieu Alexandre Weinstein | Dir, 10% | P - Purchase | $4.61 | +452,702 | 2,396,367 | +23% | +$2,086,956 | |||||
| D | 2025-11-17 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $10.59 | -1,635 | 3,594 | -31% | -$17,315 | |||||
| D | 2025-11-19 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $4.16 | -40,000 | 913,839 | -4% | -$166,400 | |||||
| D | 2025-11-17 | LENZ | Lenz Therapeutics, Inc. | Olsson Shawn | Chief Commercial Officer | S - Sale+OE | $26.10 | -10,000 | 4,733 | -68% | -$261,022 | |||||
2025-11-17 | ELUT | Elutia Inc. | Colpman David | Dir | P - Purchase | $0.74 | +15,500 | 18,598 | +500% | +$11,470 | ||||||
2025-11-17 | ATRA | Atara Biotherapeutics, Inc. | Nguyen Anhco | Pres, CEO | S - Sale | $13.19 | -2,915 | 64,974 | -4% | -$38,437 | ||||||
2025-11-17 | ATRA | Atara Biotherapeutics, Inc. | Grant-Huerta Yanina | Chief Accounting Officer | S - Sale | $13.19 | -1,804 | 33,454 | -5% | -$23,788 | ||||||
2025-11-18 | PLX | Protalix Biotherapeutics, Inc. | Bar-Shalev Amos | Dir | S - Sale | $1.87 | -168 | 7,500 | -2% | -$314 | ||||||
2025-11-17 | REPL | Replimune Group, Inc. | Sarchi Christopher | Chief Commercial Officer | S - Sale | $9.10 | -5,208 | 123,088 | -4% | -$47,393 | ||||||
2025-11-17 | REPL | Replimune Group, Inc. | Xynos Konstantinos | Chief Medical Officer | S - Sale | $9.10 | -7,248 | 139,685 | -5% | -$65,957 | ||||||
2025-11-18 | RGEN | Repligen Corp | Bylund James | COO | S - Sale | $151.21 | -2,191 | 21,520 | -9% | -$331,301 | ||||||
2025-11-17 | IPSC | Century Therapeutics, Inc. | Pfeiffenberger Brent | Pres, CEO | S - Sale | $0.45 | -32,456 | 3,236,453 | -1% | -$14,735 | ||||||
2025-11-17 | ALLO | Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | SVP, Chief Technical Officer | S - Sale | $1.22 | -786 | 217,721 | 0% | -$959 | ||||||
2025-11-17 | VIVS | Vivosim Labs, Inc. | Gobel David | Dir | S - Sale | $2.24 | -3,266 | 0 | -100% | -$7,300 | ||||||
2025-11-17 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale | $14.05 | -238 | 269,343 | 0% | -$3,344 | ||||||
2025-11-17 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $125.23 | -2,500 | 154,555 | -2% | -$313,075 | ||||||
| D | 2025-11-17 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale+OE | $125.86 | -28,000 | 107,193 | -21% | -$3,524,173 | |||||
| D | 2025-11-17 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $41.43 | -1,000 | 0 | -100% | -$41,430 | |||||
2025-11-17 | VIR | Vir Biotechnology, Inc. | O'Byrne Jason | EVP, CFO | S - Sale | $5.56 | -6,799 | 110,701 | -6% | -$37,782 | ||||||
| M | 2025-11-14 | FENC | Fennec Pharmaceuticals Inc. | Southpoint Capital Advisors LP | 10% | S - Sale | $8.27 | -246,018 | 3,764,082 | -6% | -$2,035,625 | |||||
2025-11-17 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | Pres, CEO | S - Sale | $3.38 | -6,375 | 343,999 | -2% | -$21,522 | ||||||
2025-11-17 | TNYA | Tenaya Therapeutics, Inc. | Higa Tomohiro | SVP, Finance | S - Sale | $1.33 | -1,367 | 93,971 | -1% | -$1,818 | ||||||
2025-11-17 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Chief Medical Officer | S - Sale | $1.33 | -2,877 | 169,926 | -2% | -$3,826 | ||||||
2025-11-17 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | CEO | S - Sale | $1.33 | -3,126 | 299,666 | -1% | -$4,158 | ||||||
2025-11-17 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale | $90.00 | -340 | 284 | -54% | -$30,600 | ||||||
2025-11-13 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $12.65 | +315,457 | 2,160,027 | +17% | +$3,990,531 | ||||||
2025-11-17 | AURA | Aura Biosciences, Inc. | Hopkins Janet Jill | Chief Medical Officer | S - Sale | $5.42 | -17,109 | 252,685 | -6% | -$92,731 | ||||||
2025-11-13 | BCRX | Biocryst Pharmaceuticals Inc | Sanders Machelle | Dir | S - Sale | $7.14 | -9,600 | 30,642 | -24% | -$68,544 | ||||||
| D | 2025-11-12 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $65.07 | -20,000 | 958,761 | -2% | -$1,301,410 | |||||
2025-11-14 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale | $65.00 | -2,000 | 197,871 | -1% | -$130,000 | ||||||
2025-11-13 | ELUT | Elutia Inc. | Mills C Randal | Pres, CEO | P - Purchase | $0.75 | +13,500 | 353,785 | +4% | +$10,110 | ||||||
| D | 2025-11-13 | RGEN | Repligen Corp | Hunt Anthony | Dir | S - Sale+OE | $154.61 | -20,000 | 83,695 | -19% | -$3,092,278 | |||||
| M | 2025-11-12 | PROK | Prokidney Corp. | Pereira Brian Jg | Dir | S - Sale | $2.49 | -757,162 | 0 | -100% | -$1,884,577 | |||||
2025-11-11 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale | $60.00 | -1,000 | 199,871 | 0% | -$60,000 | ||||||
2025-11-13 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $63.01 | -20,000 | 1,272,987 | -2% | -$1,260,236 | ||||||
| D | 2025-11-12 | GILD | Gilead Sciences, Inc. | Telman Deborah H | EVP, Corporate Affairs, GC | S - Sale+OE | $122.85 | -53,646 | 43,676 | -55% | -$6,590,487 | |||||
2025-11-12 | AMGN | Amgen Inc | Khosla Rachna | SVP, Business Development | S - Sale | $336.24 | -890 | 7,082 | -11% | -$299,256 | ||||||
2025-11-12 | AMGN | Amgen Inc | Gordon Murdo | EVP, Global Commercial Ops | S - Sale | $336.83 | -6,879 | 41,923 | -14% | -$2,317,071 | ||||||
2025-11-12 | EXEL | Exelixis, Inc. | Papadopoulos Stelios | Dir | S - Sale | $43.55 | -100,000 | 1,189,228 | -8% | -$4,355,000 | ||||||
2025-11-11 | EXEL | Exelixis, Inc. | Aftab Dana | EVP, Research, Development | S - Sale | $42.50 | -48,383 | 670,613 | -7% | -$2,056,278 | ||||||
| D | 2025-11-11 | EXEL | Exelixis, Inc. | Beckerle Mary C | Dir | S - Sale+OE | $41.93 | -24,622 | 21,380 | -54% | -$1,032,414 | |||||
2025-11-11 | NMRA | Neumora Therapeutics, Inc. | Aurora Daljit Singh | See Remarks | S - Sale | $2.68 | -114,703 | 88,935 | -56% | -$307,026 | ||||||
| D | 2025-11-12 | RGEN | Repligen Corp | Hunt Anthony | Dir | S - Sale+OE | $156.88 | -25,000 | 100,743 | -20% | -$3,921,940 | |||||
| D | 2025-11-11 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale+OE | $64.00 | -10,000 | 110,994 | -8% | -$640,000 | |||||
| D | 2025-11-11 | VCEL | Vericel Corp | Halpin Michael | COO | S - Sale+OE | $40.41 | -2,642 | 15,932 | -14% | -$106,763 | |||||
2025-11-10 | SLDB | Solid Biosciences Inc. | Ganot Ilan | Dir | S - Sale | $4.12 | -3,278 | 129,645 | -2% | -$13,505 | ||||||
| D | 2025-11-07 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $60.31 | -30,000 | 888,337 | -3% | -$1,809,306 | |||||
2025-11-10 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale | $14.82 | -10,000 | 1,269,524 | -1% | -$148,200 | ||||||
| M | 2025-11-10 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale | $14.73 | -89,265 | 2,869,975 | -3% | -$1,315,180 | |||||
| DM | 2025-11-10 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $69.47 | -60,000 | 733,719 | -8% | -$4,167,930 | |||||
2025-11-10 | HALO | Halozyme Therapeutics, Inc. | Connaughton Bernadette | Dir | S - Sale | $68.48 | -2,000 | 42,952 | -4% | -$136,960 | ||||||
| D | 2025-11-10 | VCEL | Vericel Corp | McLaughlin Kevin F | Dir | S - Sale+OE | $38.59 | -7,000 | 15,100 | -32% | -$270,130 | |||||
2025-11-07 | LENZ | Lenz Therapeutics, Inc. | McCollum James W | Dir | P - Purchase | $22.79 | +10,500 | 631,099 | +2% | +$239,278 | ||||||
| D | 2025-11-06 | VCEL | Vericel Corp | Halpin Michael | COO | S - Sale+OE | $40.47 | -7,358 | 15,932 | -32% | -$297,778 | |||||
| D | 2025-11-05 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $55.07 | -10,785 | 282,008 | -4% | -$593,903 | |||||
2025-11-07 | LENZ | Lenz Therapeutics, Inc. | Chevallard Daniel R. | CFO | P - Purchase | $22.76 | +2,198 | 5,386 | +69% | +$50,017 | ||||||
2025-11-05 | VIR | Vir Biotechnology, Inc. | De Verneuil Vanina | EVP, GC, Corp Sec | S - Sale | $5.16 | -2,385 | 78,210 | -3% | -$12,307 | ||||||
| D | 2025-11-05 | NBIX | Neurocrine Biosciences Inc | Rastetter William H | Dir | S - Sale+OE | $151.82 | -18,000 | 40,360 | -31% | -$2,732,690 | |||||
| D | 2025-11-04 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $5.21 | -40,000 | 954,229 | -4% | -$208,400 | |||||
2025-11-05 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $8.10 | -10,000 | 82,318 | -11% | -$81,000 | ||||||
2025-11-03 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $32.08 | -1,019 | 120,694 | -1% | -$32,689 | ||||||
2025-11-03 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $32.08 | -2,755 | 265,919 | -1% | -$88,379 | ||||||
2025-11-03 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $32.08 | -1,084 | 142,187 | -1% | -$34,774 | ||||||
| D | 2025-11-03 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $32.08 | -4,887 | 733,922 | -1% | -$156,772 | |||||
2025-11-03 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $32.08 | -160 | 50,870 | 0% | -$5,133 | ||||||
2025-11-03 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $0.59 | -292 | 405,131 | 0% | -$171 | ||||||
| D | 2025-11-04 | NBIX | Neurocrine Biosciences Inc | Gano Kyle | CEO | S - Sale+OE | $141.97 | -300 | 140,407 | 0% | -$42,591 | |||||
2025-11-03 | VIR | Vir Biotechnology, Inc. | De Verneuil Vanina | EVP, GC | S - Sale | $5.86 | -1,365 | 80,595 | -2% | -$8,003 | ||||||
| D | 2025-11-03 | DTIL | Precision Biosciences Inc | Kelly John Alexander | CFO | S - Sale+OE | $6.49 | -1,303 | 77,298 | -2% | -$8,456 | |||||
| D | 2025-11-03 | DTIL | Precision Biosciences Inc | Scimeca Dario | GC, Secretary | S - Sale+OE | $6.49 | -665 | 28,258 | -2% | -$4,316 | |||||
| D | 2025-11-03 | DTIL | Precision Biosciences Inc | Amoroso Michael | Pres, CEO | S - Sale+OE | $6.49 | -3,409 | 115,575 | -3% | -$22,124 | |||||
2025-11-03 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Pres, CEO | S - Sale | $7.00 | -62,073 | 1,590,118 | -4% | -$434,511 | ||||||
2025-11-03 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $5.64 | -22,000 | 1,210,391 | -2% | -$124,047 | ||||||
2025-10-30 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $31.44 | -6,515 | 121,713 | -5% | -$204,860 | ||||||
2025-10-30 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $31.44 | -17,606 | 268,674 | -6% | -$553,608 | ||||||
2025-10-30 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $31.44 | -6,920 | 143,271 | -5% | -$217,595 | ||||||
| D | 2025-10-30 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $31.44 | -31,379 | 738,809 | -4% | -$986,691 | |||||
2025-10-30 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $31.44 | -5,517 | 111,008 | -5% | -$173,478 | ||||||
2025-10-30 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $31.44 | -1,016 | 51,030 | -2% | -$31,947 | ||||||
| M | 2025-10-28 | VOR | Vor Biopharma Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $25.90 | -400,408 | 779,652 | -34% | -$10,368,938 | |||||
2025-10-28 | CGEM | Cullinan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $8.40 | +165,667 | 8,963,500 | +2% | +$1,391,686 | ||||||
| M | 2025-10-28 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $6.50 | -24,553 | 14,573,983 | 0% | -$159,655 | |||||
| M | 2025-10-28 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $7.40 | -40,529 | 337,469 | -11% | -$299,949 | |||||
2025-10-28 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $7.29 | -21,664 | 313,631 | -6% | -$157,931 | ||||||
2025-10-28 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $7.29 | -30,897 | 521,823 | -6% | -$225,239 | ||||||
2025-10-27 | NMRA | Neumora Therapeutics, Inc. | Burow Kristina | Dir, 10% | P - Purchase | $2.61 | +1,915,700 | 33,895,555 | +6% | +$4,999,977 | ||||||
2025-10-27 | NMRA | Neumora Therapeutics, Inc. | Arch Venture Partners Xii, LLC | 10% | P - Purchase | $2.61 | +1,915,700 | 33,847,838 | +6% | +$4,999,977 | ||||||
2025-10-27 | NMRA | Neumora Therapeutics, Inc. | Arch Venture Partners X, LLC | 10% | P - Purchase | $2.61 | +1,915,700 | 33,847,838 | +6% | +$4,999,977 | ||||||
| D | 2025-10-29 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | CEO | S - Sale+OE | $60.99 | -30,000 | 660,482 | -4% | -$1,829,737 | |||||
2025-10-29 | AURA | Aura Biosciences, Inc. | Elazzouzi Amy | SVP, Finance | S - Sale | $6.35 | -896 | 85,662 | -1% | -$5,690 | ||||||
2025-10-29 | AURA | Aura Biosciences, Inc. | De Los Pinos Elisabet | See Remarks | S - Sale | $6.35 | -9,049 | 602,154 | -1% | -$57,461 | ||||||
2025-10-28 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $119.39 | -10,000 | 581,203 | -2% | -$1,193,926 | ||||||
2025-10-27 | BEAM | Beam Therapeutics Inc. | Fmr LLC | See Remark 1, 10% | S - Sale | $26.68 | -459 | 1,980,688 | 0% | -$12,246 | ||||||
| M | 2025-10-24 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $6.01 | -113,099 | 14,598,536 | -1% | -$679,870 | |||||
| M | 2025-10-23 | VOR | Vor Biopharma Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $28.06 | -221,166 | 1,180,060 | -16% | -$6,204,863 | |||||
2025-10-23 | XFOR | X4 Pharmaceuticals, Inc | Craig Adam R | Exec COB | P - Purchase | $2.90 | +86,206 | 376,087 | +30% | +$249,997 | ||||||
| D | 2025-10-24 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $12.00 | -2,678 | 3,594 | -43% | -$32,136 | |||||
2025-10-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $30.88 | -2,240 | 206,495 | -1% | -$69,160 | ||||||
| D | 2025-10-24 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $16.00 | -21,000 | 3,744,233 | -1% | -$336,000 | |||||
| D | 2025-10-23 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $5.70 | -100,000 | 954,229 | -9% | -$570,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |